Susan G. Komen
@susangkomen.bsky.social
Breast cancer research
Breast cancer care & financial support
Breast health advocacy & public policy
Breast cancer care & financial support
Breast health advocacy & public policy
Breast cancer screening and early detection play an important role in your health. Screening tests can help find breast cancer at an early stage when the chances of survival are highest.
Learn more about cancer screening: https://bit.ly/48RfhN7
Learn more about cancer screening: https://bit.ly/48RfhN7
December 5, 2025 at 3:49 PM
Breast cancer screening and early detection play an important role in your health. Screening tests can help find breast cancer at an early stage when the chances of survival are highest.
Learn more about cancer screening: https://bit.ly/48RfhN7
Learn more about cancer screening: https://bit.ly/48RfhN7
The fight against breast cancer matters. That’s why we are committed to transparency and accountability in everything we do.
Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE
Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE
November 23, 2025 at 6:22 PM
The fight against breast cancer matters. That’s why we are committed to transparency and accountability in everything we do.
Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE
Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE
Breast cancer is emerging as a global health crisis, yet with support from Komen, a groundbreaking tool called the Breast Cancer Care Quality Index is providing countries a roadmap to improve breast cancer care & save lives, regardless of the resources they have.
Learn more: https://bit.ly/3X34dG8
Learn more: https://bit.ly/3X34dG8
November 18, 2025 at 6:10 PM
Breast cancer is emerging as a global health crisis, yet with support from Komen, a groundbreaking tool called the Breast Cancer Care Quality Index is providing countries a roadmap to improve breast cancer care & save lives, regardless of the resources they have.
Learn more: https://bit.ly/3X34dG8
Learn more: https://bit.ly/3X34dG8
Drumroll please! 🥁
We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll.
And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!
We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll.
And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!
November 11, 2025 at 4:11 PM
Drumroll please! 🥁
We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll.
And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!
We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll.
And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!
🌍🔬 At ESMO 2025, breast cancer news went off:
📍Chemo-free options for HER2+
📍Improved options in TNBC
📍Keeping cancer recurrence at bay
📍New options for metastatic ER+ BC
Read the highlights in our blog: https://bit.ly/4hHohat
📍Chemo-free options for HER2+
📍Improved options in TNBC
📍Keeping cancer recurrence at bay
📍New options for metastatic ER+ BC
Read the highlights in our blog: https://bit.ly/4hHohat
November 5, 2025 at 5:14 PM
🌍🔬 At ESMO 2025, breast cancer news went off:
📍Chemo-free options for HER2+
📍Improved options in TNBC
📍Keeping cancer recurrence at bay
📍New options for metastatic ER+ BC
Read the highlights in our blog: https://bit.ly/4hHohat
📍Chemo-free options for HER2+
📍Improved options in TNBC
📍Keeping cancer recurrence at bay
📍New options for metastatic ER+ BC
Read the highlights in our blog: https://bit.ly/4hHohat
Many new treatments for MBC today are under study in clinical trials. Patient navigator Miranda Zinn shares how she and her team of navigators in the Komen Patient Care Center support the MBC community by guiding them to the right clinical trials.
Learn more: https://bit.ly/4opdC72
Learn more: https://bit.ly/4opdC72
November 4, 2025 at 4:07 PM
Many new treatments for MBC today are under study in clinical trials. Patient navigator Miranda Zinn shares how she and her team of navigators in the Komen Patient Care Center support the MBC community by guiding them to the right clinical trials.
Learn more: https://bit.ly/4opdC72
Learn more: https://bit.ly/4opdC72
Dr. Rebecca Dent shared TROPION-Breast02 results:
Dato-DXd outdid chemo as 1st line treatment for metastatic TNBC patients ineligible for immunotherapy
✅ Longer survival: 24 vs 18.7 mo; 21% ⬇️death risk
✅ Cancer stayed controlled longer: 9.6 vs 5.2 mo (4/4)
Dato-DXd outdid chemo as 1st line treatment for metastatic TNBC patients ineligible for immunotherapy
✅ Longer survival: 24 vs 18.7 mo; 21% ⬇️death risk
✅ Cancer stayed controlled longer: 9.6 vs 5.2 mo (4/4)
October 19, 2025 at 5:18 PM
Dr. Rebecca Dent shared TROPION-Breast02 results:
Dato-DXd outdid chemo as 1st line treatment for metastatic TNBC patients ineligible for immunotherapy
✅ Longer survival: 24 vs 18.7 mo; 21% ⬇️death risk
✅ Cancer stayed controlled longer: 9.6 vs 5.2 mo (4/4)
Dato-DXd outdid chemo as 1st line treatment for metastatic TNBC patients ineligible for immunotherapy
✅ Longer survival: 24 vs 18.7 mo; 21% ⬇️death risk
✅ Cancer stayed controlled longer: 9.6 vs 5.2 mo (4/4)
Dr. Javier Cortes on ASCENT-03: Sacituzumab govitecan vs chemo as 1st treatment for metastatic TNBC ineligible for immunotherapy
✅ Cancer stayed controlled longer: 9.7 vs 6.9 mo ⬇️38% risk of progression
✅ longer lasting response to treatment
✅ Fewer stopped treatment 4% vs 12%
✅ Cancer stayed controlled longer: 9.7 vs 6.9 mo ⬇️38% risk of progression
✅ longer lasting response to treatment
✅ Fewer stopped treatment 4% vs 12%
October 19, 2025 at 5:18 PM
Dr. Javier Cortes on ASCENT-03: Sacituzumab govitecan vs chemo as 1st treatment for metastatic TNBC ineligible for immunotherapy
✅ Cancer stayed controlled longer: 9.7 vs 6.9 mo ⬇️38% risk of progression
✅ longer lasting response to treatment
✅ Fewer stopped treatment 4% vs 12%
✅ Cancer stayed controlled longer: 9.7 vs 6.9 mo ⬇️38% risk of progression
✅ longer lasting response to treatment
✅ Fewer stopped treatment 4% vs 12%
Dr. Sibylle Loibl shared DESTINY-Breast09 subgroup results:
T-DXd + pertuzumab as 1st treatment for HER2+ MBC outperformed standard therapy regardless of:
✅ Prior treatment
✅ Hormone receptor status
✅ PIK3CA mutations
T-DXd + pertuzumab as 1st treatment for HER2+ MBC outperformed standard therapy regardless of:
✅ Prior treatment
✅ Hormone receptor status
✅ PIK3CA mutations
October 19, 2025 at 5:18 PM
Dr. Sibylle Loibl shared DESTINY-Breast09 subgroup results:
T-DXd + pertuzumab as 1st treatment for HER2+ MBC outperformed standard therapy regardless of:
✅ Prior treatment
✅ Hormone receptor status
✅ PIK3CA mutations
T-DXd + pertuzumab as 1st treatment for HER2+ MBC outperformed standard therapy regardless of:
✅ Prior treatment
✅ Hormone receptor status
✅ PIK3CA mutations
🌍🔬 Day 3 #ESMO25 highlights:
📍Antibody drug conjugates transforming 1st-line treatment in metastatic breast cancer
📍Improved survival and longer disease control in HER2+ and TNBC
@myesmo.bsky.social #breastcancer (1/4)
📍Antibody drug conjugates transforming 1st-line treatment in metastatic breast cancer
📍Improved survival and longer disease control in HER2+ and TNBC
@myesmo.bsky.social #breastcancer (1/4)
October 19, 2025 at 5:18 PM
🌍🔬 Day 3 #ESMO25 highlights:
📍Antibody drug conjugates transforming 1st-line treatment in metastatic breast cancer
📍Improved survival and longer disease control in HER2+ and TNBC
@myesmo.bsky.social #breastcancer (1/4)
📍Antibody drug conjugates transforming 1st-line treatment in metastatic breast cancer
📍Improved survival and longer disease control in HER2+ and TNBC
@myesmo.bsky.social #breastcancer (1/4)
Dr. Charles Geyer presented DESTINY-Breast05: T-DXd vs T-DM1 in HER2+ early BC given after initial treatment for those who have cancer remaining after neoadjuvant treatment.
✅ T-DXd cut recurrence risk by ~50%
💊 T-DXd poised to replace T-DM1 as SOC (5/5)
✅ T-DXd cut recurrence risk by ~50%
💊 T-DXd poised to replace T-DM1 as SOC (5/5)
October 19, 2025 at 1:04 AM
Dr. Charles Geyer presented DESTINY-Breast05: T-DXd vs T-DM1 in HER2+ early BC given after initial treatment for those who have cancer remaining after neoadjuvant treatment.
✅ T-DXd cut recurrence risk by ~50%
💊 T-DXd poised to replace T-DM1 as SOC (5/5)
✅ T-DXd cut recurrence risk by ~50%
💊 T-DXd poised to replace T-DM1 as SOC (5/5)
Dr. Nadia Harbeck shared DESTINY-Breast11 results: Neoadjuvant T-DXd with & w/o THP performed better than anthracycline-based chemo in high-risk HER2+ early BC
📈 Pathologic complete response 67% vs 56% (+11%)
✅ Fewer adverse events, less cardiac toxicity
(4/5)
📈 Pathologic complete response 67% vs 56% (+11%)
✅ Fewer adverse events, less cardiac toxicity
(4/5)
October 19, 2025 at 1:04 AM
Dr. Nadia Harbeck shared DESTINY-Breast11 results: Neoadjuvant T-DXd with & w/o THP performed better than anthracycline-based chemo in high-risk HER2+ early BC
📈 Pathologic complete response 67% vs 56% (+11%)
✅ Fewer adverse events, less cardiac toxicity
(4/5)
📈 Pathologic complete response 67% vs 56% (+11%)
✅ Fewer adverse events, less cardiac toxicity
(4/5)
Dr. Sara Hurvitz presented VIKTORIA-1, where gedatolisib + fulvestrant ± palbociclib significantly extended progression-free survival for HR+/HER2-, PIK3CA wild-type advanced BC
✅ Triplet: 9.3 months vs 2
✅ Doublet: 7.4 vs 2
📍Possible new option post-CDK4/6 treatment( 3/5)
✅ Triplet: 9.3 months vs 2
✅ Doublet: 7.4 vs 2
📍Possible new option post-CDK4/6 treatment( 3/5)
October 19, 2025 at 1:04 AM
Dr. Sara Hurvitz presented VIKTORIA-1, where gedatolisib + fulvestrant ± palbociclib significantly extended progression-free survival for HR+/HER2-, PIK3CA wild-type advanced BC
✅ Triplet: 9.3 months vs 2
✅ Doublet: 7.4 vs 2
📍Possible new option post-CDK4/6 treatment( 3/5)
✅ Triplet: 9.3 months vs 2
✅ Doublet: 7.4 vs 2
📍Possible new option post-CDK4/6 treatment( 3/5)
Dr. Erica Mayer presented evERA trial data: Oral SERD giredestrant + everolimus doubled response rates & cut risk of progression by ~60% vs standard HT after CDK4/6 inhibitors
📈 Greatest impact in ESR1-mutant tumors
💊 Potential oral, well-tolerated option for post-CDK4/6 (2/5)
📈 Greatest impact in ESR1-mutant tumors
💊 Potential oral, well-tolerated option for post-CDK4/6 (2/5)
October 19, 2025 at 1:04 AM
Dr. Erica Mayer presented evERA trial data: Oral SERD giredestrant + everolimus doubled response rates & cut risk of progression by ~60% vs standard HT after CDK4/6 inhibitors
📈 Greatest impact in ESR1-mutant tumors
💊 Potential oral, well-tolerated option for post-CDK4/6 (2/5)
📈 Greatest impact in ESR1-mutant tumors
💊 Potential oral, well-tolerated option for post-CDK4/6 (2/5)
🌍🔬 Day 2 #ESMO25 highlights:
📍Potential new post-CDK4/6 options for ER+/HER2- metastatic BC
📍ADCs in early HER2+ breast cancer
@myESMO #breastcancer (1/5)
📍Potential new post-CDK4/6 options for ER+/HER2- metastatic BC
📍ADCs in early HER2+ breast cancer
@myESMO #breastcancer (1/5)
October 19, 2025 at 1:04 AM
🌍🔬 Day 2 #ESMO25 highlights:
📍Potential new post-CDK4/6 options for ER+/HER2- metastatic BC
📍ADCs in early HER2+ breast cancer
@myESMO #breastcancer (1/5)
📍Potential new post-CDK4/6 options for ER+/HER2- metastatic BC
📍ADCs in early HER2+ breast cancer
@myESMO #breastcancer (1/5)
Dr. J Crown shared 5-year results from the NATALEE trial 🧬
Adjuvant ribociclib + aromatase inhibitors showed lasting benefit in HR+/HER2- early BC
✅ ~28% lower risk of recurrence or death
✅ Benefit seen even in node-neg (4/4)
Adjuvant ribociclib + aromatase inhibitors showed lasting benefit in HR+/HER2- early BC
✅ ~28% lower risk of recurrence or death
✅ Benefit seen even in node-neg (4/4)
October 17, 2025 at 7:38 PM
Dr. J Crown shared 5-year results from the NATALEE trial 🧬
Adjuvant ribociclib + aromatase inhibitors showed lasting benefit in HR+/HER2- early BC
✅ ~28% lower risk of recurrence or death
✅ Benefit seen even in node-neg (4/4)
Adjuvant ribociclib + aromatase inhibitors showed lasting benefit in HR+/HER2- early BC
✅ ~28% lower risk of recurrence or death
✅ Benefit seen even in node-neg (4/4)
Dr. S Johnston shared a 1st look at overall survival in the monarchE trial:
Abemaciclib + hormone therapy improved OS in node+ HR+/HER2- early BC
✅Risk of death reduced by15.8%
✅Metastases reduced (14% vs 20%)
✅First CDK4/6 inhibitor to show OS gain in adjuvant setting (3/4)
Abemaciclib + hormone therapy improved OS in node+ HR+/HER2- early BC
✅Risk of death reduced by15.8%
✅Metastases reduced (14% vs 20%)
✅First CDK4/6 inhibitor to show OS gain in adjuvant setting (3/4)
October 17, 2025 at 7:38 PM
Dr. S Johnston shared a 1st look at overall survival in the monarchE trial:
Abemaciclib + hormone therapy improved OS in node+ HR+/HER2- early BC
✅Risk of death reduced by15.8%
✅Metastases reduced (14% vs 20%)
✅First CDK4/6 inhibitor to show OS gain in adjuvant setting (3/4)
Abemaciclib + hormone therapy improved OS in node+ HR+/HER2- early BC
✅Risk of death reduced by15.8%
✅Metastases reduced (14% vs 20%)
✅First CDK4/6 inhibitor to show OS gain in adjuvant setting (3/4)
Dr. Fedro Peccatori gave a 5-year update from the POSITIVE Trial confirming it remains safe to pause (and later resume) hormone therapy to conceive for those with HR+ early BC.
Data showed:
✅ No rise in recurrence
✅ High pregnancy rate >76% & birth rate >90% (2/4)
Data showed:
✅ No rise in recurrence
✅ High pregnancy rate >76% & birth rate >90% (2/4)
October 17, 2025 at 7:38 PM
Dr. Fedro Peccatori gave a 5-year update from the POSITIVE Trial confirming it remains safe to pause (and later resume) hormone therapy to conceive for those with HR+ early BC.
Data showed:
✅ No rise in recurrence
✅ High pregnancy rate >76% & birth rate >90% (2/4)
Data showed:
✅ No rise in recurrence
✅ High pregnancy rate >76% & birth rate >90% (2/4)
🌍🔬Day 1 #ESMO25 highlights:
📍Pregnancy safety in HR+ breast cancer
📍New practice-confirming insight into adjuvant CDK4/6 inhibitors for early HR+/HER2- breast cancer
@myESMO #breastcancer (1/4)
📍Pregnancy safety in HR+ breast cancer
📍New practice-confirming insight into adjuvant CDK4/6 inhibitors for early HR+/HER2- breast cancer
@myESMO #breastcancer (1/4)
October 17, 2025 at 7:38 PM
🌍🔬Day 1 #ESMO25 highlights:
📍Pregnancy safety in HR+ breast cancer
📍New practice-confirming insight into adjuvant CDK4/6 inhibitors for early HR+/HER2- breast cancer
@myESMO #breastcancer (1/4)
📍Pregnancy safety in HR+ breast cancer
📍New practice-confirming insight into adjuvant CDK4/6 inhibitors for early HR+/HER2- breast cancer
@myESMO #breastcancer (1/4)
It’s #ESMO25 week 🎗️
We’re tracking new data and key breast cancer studies at the European Society for Medical Oncology.
Follow us along here & on X for highlights and updates 💗
#BreastCancer #Oncology @myesmo.bsky.social
We’re tracking new data and key breast cancer studies at the European Society for Medical Oncology.
Follow us along here & on X for highlights and updates 💗
#BreastCancer #Oncology @myesmo.bsky.social
October 16, 2025 at 3:54 PM
It’s #ESMO25 week 🎗️
We’re tracking new data and key breast cancer studies at the European Society for Medical Oncology.
Follow us along here & on X for highlights and updates 💗
#BreastCancer #Oncology @myesmo.bsky.social
We’re tracking new data and key breast cancer studies at the European Society for Medical Oncology.
Follow us along here & on X for highlights and updates 💗
#BreastCancer #Oncology @myesmo.bsky.social
Today is National Donor Advised Fund Day! Consider using our quick and easy tool to make an immediate impact. Now more than ever, patients need your help.
Ending breast cancer needs all of us. Komen.org/DAF #DAFDay
Ending breast cancer needs all of us. Komen.org/DAF #DAFDay
October 9, 2025 at 2:01 PM
Today is National Donor Advised Fund Day! Consider using our quick and easy tool to make an immediate impact. Now more than ever, patients need your help.
Ending breast cancer needs all of us. Komen.org/DAF #DAFDay
Ending breast cancer needs all of us. Komen.org/DAF #DAFDay
For someone with breast cancer, genomic testing can be a personalized guide that helps themchoose a treatment path with the greatest benefit while possibly avoiding unnecessary detours.
Read more in the latest Know More blog: https://www.komen.org/blog/know-more-genomic-testing/
Read more in the latest Know More blog: https://www.komen.org/blog/know-more-genomic-testing/
October 6, 2025 at 7:11 PM
For someone with breast cancer, genomic testing can be a personalized guide that helps themchoose a treatment path with the greatest benefit while possibly avoiding unnecessary detours.
Read more in the latest Know More blog: https://www.komen.org/blog/know-more-genomic-testing/
Read more in the latest Know More blog: https://www.komen.org/blog/know-more-genomic-testing/
4 years ago, we released a first-of-its-kind report highlighting the breast cancer disparities bet. Black & white women. Today, we’re sharing an update: in 9 major U.S. metro areas where outcomes were the worst, more Black lives are being saved from breast cancer.
Read more: https://bit.ly/4ojeKsz
Read more: https://bit.ly/4ojeKsz
October 1, 2025 at 1:52 PM
4 years ago, we released a first-of-its-kind report highlighting the breast cancer disparities bet. Black & white women. Today, we’re sharing an update: in 9 major U.S. metro areas where outcomes were the worst, more Black lives are being saved from breast cancer.
Read more: https://bit.ly/4ojeKsz
Read more: https://bit.ly/4ojeKsz
October is National Breast Cancer Awareness Month and it's time to take action. From advocating for cancer research funding to supporting equitable care for all, your voice matters!
Visit komen.org to join the fight. Because ending breast cancer needs all of us.
Visit komen.org to join the fight. Because ending breast cancer needs all of us.
September 30, 2025 at 3:17 PM
October is National Breast Cancer Awareness Month and it's time to take action. From advocating for cancer research funding to supporting equitable care for all, your voice matters!
Visit komen.org to join the fight. Because ending breast cancer needs all of us.
Visit komen.org to join the fight. Because ending breast cancer needs all of us.
In case you missed it, check out the latest Breast Cancer Breakthroughs focused on how ctDNA is poised to revolutionize breast cancer care and read our blog to learn what it means for patients.
Watch the event & read the blog here: https://bit.ly/48C56MO
Watch the event & read the blog here: https://bit.ly/48C56MO
September 26, 2025 at 8:49 PM
In case you missed it, check out the latest Breast Cancer Breakthroughs focused on how ctDNA is poised to revolutionize breast cancer care and read our blog to learn what it means for patients.
Watch the event & read the blog here: https://bit.ly/48C56MO
Watch the event & read the blog here: https://bit.ly/48C56MO